Moffitt Cancer Center's Institute Board of Directors today announced the creation of a Personalized Medicine Institute aimed at making a national impact in the war on cancer by delivering on the promise of personalized cancer care. Moffitt Chief Executive Officer William S. Dalton, Ph.D., M.D., will dedicate his entire focus to the establishment of the new institute and the growth of Moffitt's innovative biotechnology subsidiary M2GenTM as its CEO. Alan F. List, M.D., will advance to CEO of Moffitt. Thomas A. Sellers, Ph.D., will assume the role of center director. The changes will take effect in July.
Moffitt Board Chairman Robert Rothman noted that these changes, driven by the board in collaboration with Dalton, ensure that the right leaders are in place to take Moffitt and M2GenTM to the next level as a national model for transforming the fight against cancer.
"The time is now because cancer research and treatment is at an inflection point that requires the right mix of visionary leadership and collaboration to realize the promise of personalized cancer care for patients everywhere. Moffitt, under Dr. Dalton's leadership, is considered a national leader in personalized medicine, and we must capitalize on our success in this important area," Rothman said.
Read the full story: http://hcp.lv/yMGllW
Source: OBR Daily
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More